Merus NV Quote - MRUS

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

56.78

Bid

53.65

Ask

59.38

Volume

870,386

55.74 Day's Range 57.63

19.805 52 Week Range 61.61

Market Cap

Previous Close

56.91

Open

57.00

Last Trade

277100

56.78

(average)

Last Trade Time

15:58:13

Financial Volume

US$ 49,371,447

VWAP

56.7236

Average Volume (3m)

986,761

Shares Outstanding

58,687,551

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector

Gen Med & Surgical Hospitals

Industry

Gen Med & Surgical Hospitals

Website

www.merus.nl

Headquarters

Utrecht, Utrecht, Nld

Founded

1970

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was US$56.91. Over the last year, Merus NV shares have traded in a share price range of US$ 19.805 to US$ 61.61.

Merus NV currently has 58,687,551 shares outstanding.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.02	1.82926829268	55.76	57.63	53.01	689293	55.11909299	CS
4	-2.21	-3.74639769452	58.99	59.66	48.93	1295494	54.62430142	CS
12	12.43	28.0270574972	44.35	61.61	39.27	986761	50.5798052	CS
26	29.29	106.547835577	27.49	61.61	27.11	766820	46.7381559	CS
52	31.03	120.504854369	25.75	61.61	19.805	550253	39.51205705	CS
156	34.45	154.276757725	22.33	61.61	12.03	400608	30.2150383	CS
260	42.96	310.853835022	13.82	61.61	10.18	285694	28.21167527	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AXISAxis Auto Finance Inc	$ 0.045 (28.57%)	1,000
NCFNorthcliff Resources Ltd	$ 0.025 (25.00%)	10k
AMMAlmaden Minerals Ltd New	$ 0.105 (23.53%)	154.73k
GFPGreenFirst Forest Products Inc	$ 0.40 (21.21%)	382.15k
AVCNAvicanna Inc	$ 0.35 (18.64%)	437.61k
VGCXVictoria Gold Corp	$ 1.36 (-81.70%)	61.51k
SCYScandium International Mining Corp	$ 0.015 (-40.00%)	19k
DNDelta 9 Cannabis Inc	$ 0.01 (-33.33%)	2.01M
NCPNickel Creek Platinum Corp	$ 0.015 (-25.00%)	38.72k
SMCSulliden Mining Capital Inc	$ 0.015 (-25.00%)	612.1k
TRPTC Energy Corporation	$ 53.49 (0.19%)	20.76M
FCUFission Uranium Corp	$ 1.17 (-1.68%)	8.51M
CNQCanadian Natural Resources Ltd	$ 48.38 (-0.72%)	6.87M
MFCManulife Financial Corporation	$ 36.16 (1.03%)	6.49M
BTEBaytex Energy Corp	$ 4.68 (-0.21%)	4.87M